Here are the 10-K annual reports from INVO Fertility, Inc. (IVF) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow IVF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IVF filings page.
INVO Fertility, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add Part III information that was not included because a proxy statement was not filed within 120 days. The amendment provides updated details on directors, executive compensation, equity plans, related-party transactions, and auditor fees.
The company describes a Clawback Policy adopted in 2023 and explains that accounting errors in its 2025 interim financial statements led to restatements, but did not affect revenue or loss from operations and did not trigger recovery of incentive pay. It also highlights outstanding options under the 2019 Stock Incentive Plan and notes that no stockholder owns more than 5% of its common shares.
INVO Fertility, Inc. files its annual report describing a fertility-focused healthcare services and technology business built around four U.S. clinics and the INVOcell intravaginal culture device. The company has shifted from a device-centric model toward owning and operating fertility clinics, including Wisconsin Fertility Institute and the 2026 acquisition of Family Beginnings in Indiana.
The filing highlights significant financing activity, including a $9.5 million January 2025 public offering, a $4.0 million December 2025 private placement, multiple warrant inducement deals, and complex preferred stock and debenture exchanges with Five Narrow Lane. These transactions, along with reverse stock splits and large increases in authorized shares, reflect ongoing efforts to raise capital and manage leverage.
INVO reports an accumulated net loss of $91.4 million since inception and states there is substantial doubt about its ability to continue as a going concern, citing high secured indebtedness, a large cash requirement, and dependence on future capital raising. The company also notes Nasdaq deficiency letters for late 10-K and 10-Q filings, a $6.0 million settlement obligation related to the Wisconsin Fertility acquisition, and extensive risk factors around regulation, data security, clinic operations, and dilution risk.